A pharmaceutical industry association lawsuit challenging California’s new drug pricing law adds to the list of alleged constitutional violations drugmakers have asserted in similar litigation this year.
In thosesuits, drugmakers alleged Nevada and Maryland drug pricing statutes violated their Fourteenth Amendment due process rights; the Supremacy Clause, which says federal law trumps state law; the Takings Clause, barring the taking of private property without just compensation; and the “Dormant” Commerce Clause, which infers that Congress’ power to regulate interstate commerce means states cannot unduly burden interstate commerce.
The Pharmaceutical Research and Manufacturers of America’s suit over California’s Senate Bill No. 17 offers up a new argument—a violation of drugmakers’ First Amendment free-speech rights. The law, which Gov. Jerry Brown (D) signed Oct. 9, requires drugmakers to give 60 days’ notice to health-care payers of a price increase in certain circumstances and requires them to justify it as either a change or improvement in the drug.
That is compelled speech barred by the First Amendment, PhRMA asserts in its suit, which was filed this month.
PhRMA’s concern is that the state is “telling them to explain something that, in their minds, they don’t have to explain,” Brian Rye, a health-care policy analyst with Bloomberg Intelligence.
The industry essentially is asking, “Why don’t other businesses have to do this?” Rye told Bloomberg Law. “If the price of a Coke goes up 10 percent, [Coca-Cola] doesn’t have to explain that to the authorities.”
PhRMA also argues requiring drugmakers to announce price hikes ahead of time will allow competitors to adjust, creating anticompetitive consequences that reverberate beyond California.
According to the group, “if you have to provide this advanced notification of your intent to [raise prices],” Rye said, “you have 50 different state markets that you’re dealing with and others as well outside the U.S.”
California’s advanced notice requirement stands out among laws passed and bills advanced in other states, said Stephane Trunk, a partner in Arent Fox LLP’s health-care practice and a Bloomberg Law advisory board member.
Vermont, Ohio, and Massachusetts are among other states pushing for drug price transparency.
How the PhRMA suit plays out in California could affect other states’ efforts, Trunk told Bloomberg Law.
“This has kind of been touted as the model bill that was going to be rolled out in other states, more so than the Maryland or Nevada bills,” Trunk said. “So I think this is definitely one to watch.”
Read my full story on PhRMA’s suit here.
Stay on top of new developments in health law and regulation, and learn more, by signing up for a free trial to Bloomberg Law.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to firstname.lastname@example.org.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to email@example.com.
Put me on standing order
Notify me when new releases are available (no standing order will be created)